Kythera Biopharmaceuticals Inc (KYTH) 74.98 $KYTH
Allergan (AGN) Projects Revenues to Surpass $8B in 2H15
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 3:30PM CDT
Allergan plc (AGN) expects revenues to cross $8 billion in the second half of 2015 and achieve double-digit top-line growth post Teva deal.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01), TEVA: 53.01 (-0.30), REGN: 372.03 (-9.05)
KYTHERA Files IND Application for Male Hair Loss Treatment
Zacks Equity Research - Zacks Investment Research - Wed Sep 23, 4:05PM CDT
KYTHERA (KYTH) has filed an investigational new drug application for KYTH-105 for the treatment of male pattern hair loss.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01)
Allergan (AGN) to Buy Eye Care Device Company AqueSys
Zacks Equity Research - Zacks Investment Research - Fri Sep 04, 3:15PM CDT
Allergan plc (AGN) announced that it has entered into an agreement to acquire AqueSys, Inc.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01), REGN: 372.03 (-9.05)
Allergan Buys Naurex, Boosts Mental Health Portfolio
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 3:20PM CDT
Allergan (AGN) acquires central nervous system focused company, Naurex, to boost mental disorder portfolio.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01), RDY: 45.10 (-0.69)
KYTHERA Files Regulatory Application for Kybella in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 3:30PM CDT
KYTHERA Biopharmaceuticals (KYTH) announced the filing of a regulatory application for Kybella) in the EU for the reduction of submental fat.
AGN: 240.93 (-6.47), VRX: 24.14 (-1.34), KYTH: 74.98 (-0.01), HSP: 89.95 (-0.01)
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
GlobeNewswire - Tue Aug 18, 8:00AM CDT
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as a treatment for the reduction of submental fat when the presence of submental fat has a psychological impact for the patient. The MAA was submitted via the Decentralized Procedure with Sweden as the Reference Member State and is supported by results from four pivotal Phase III trials conducted in Europe and North America. More than 1,500 patients participated in these trials with 757 patients treated with ATX-101.
KYTH: 74.98 (-0.01)
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update
GlobeNewswire - Thu Aug 06, 3:22PM CDT
Westlake Village, Calif., Aug. 6, 2015 - KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter of 2015, and provided an update on recent developments.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration
GlobeNewswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
PR Newswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA
GlobeNewswire - Mon Jul 27, 4:45PM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's pending acquisition of KYTHERA.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)
GlobeNewswire - Mon Jul 27, 8:00AM CDT
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has received authorization from Health Canada to market BELKYRA(TM) "for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults." BELKYRA(TM) is a non-surgical treatment for improving the appearance and profile of submental fullness--more commonly known as "double chin," a facial aesthetic condition that affects both women and men. BELKYRA(TM) was recently launched in the U.S. under the brand name KYBELLA(TM).
KYTH: 74.98 (-0.01)
Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories
PR Newswire - Mon Jul 20, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), and Impax Laboratories Inc. (NASDAQ: IPXL). Free research report on Pfizer can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PFE On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IPXL: 32.45 (-1.11), KYTH: 74.98 (-0.01), PFE: 35.29 (-0.02), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08)
Allergan (AGN) Eyes Dry Eye Disease Company, Oculeve - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 07, 8:00AM CDT
Allergan (AGN), which has been pretty active on the acquisition front, has now signed a deal to acquire development-stage medical device company, Oculeve.
AGN: 240.93 (-6.47), PGNX: 4.64 (-0.04), KYTH: 74.98 (-0.01), TEVA: 53.01 (-0.30)
KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.
PR Newswire - Fri Jun 26, 4:39PM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. ("Kythera" or the "Company"
(NasdaqGS: KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company's stockholders will only receive approximately $75 per share for each share of Kythera common stock they own.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Kythera Biopharmaceuticals (KYTH) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 26, 8:14AM CDT
Kythera Biopharmaceuticals (KYTH) is Overbought: Is A Drop Coming?
KYTH: 74.98 (-0.01)
KYTH INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of KYTHERA Biopharmaceuticals, Inc. Concerning the Sale of the Company to Allergan plc
BusinessWire - Wed Jun 24, 1:19PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (NASDAQGS: KYTH) ("KYTHERA" or "the Company" in connection with the sale of the Company to Allergan plc (NYSE: AGN).
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan (AGN) Projects Revenues to Surpass $8B in 2H15
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 3:30PM CDT
Allergan plc (AGN) expects revenues to cross $8 billion in the second half of 2015 and achieve double-digit top-line growth post Teva deal.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01), TEVA: 53.01 (-0.30), REGN: 372.03 (-9.05)
KYTHERA Files IND Application for Male Hair Loss Treatment
Zacks Equity Research - Zacks Investment Research - Wed Sep 23, 4:05PM CDT
KYTHERA (KYTH) has filed an investigational new drug application for KYTH-105 for the treatment of male pattern hair loss.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01)
Allergan (AGN) to Buy Eye Care Device Company AqueSys
Zacks Equity Research - Zacks Investment Research - Fri Sep 04, 3:15PM CDT
Allergan plc (AGN) announced that it has entered into an agreement to acquire AqueSys, Inc.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01), REGN: 372.03 (-9.05)
Allergan Buys Naurex, Boosts Mental Health Portfolio
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 3:20PM CDT
Allergan (AGN) acquires central nervous system focused company, Naurex, to boost mental disorder portfolio.
AGN: 240.93 (-6.47), GILD: 84.45 (-1.32), KYTH: 74.98 (-0.01), RDY: 45.10 (-0.69)
KYTHERA Files Regulatory Application for Kybella in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 3:30PM CDT
KYTHERA Biopharmaceuticals (KYTH) announced the filing of a regulatory application for Kybella) in the EU for the reduction of submental fat.
AGN: 240.93 (-6.47), VRX: 24.14 (-1.34), KYTH: 74.98 (-0.01), HSP: 89.95 (-0.01)
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
GlobeNewswire - Tue Aug 18, 8:00AM CDT
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as a treatment for the reduction of submental fat when the presence of submental fat has a psychological impact for the patient. The MAA was submitted via the Decentralized Procedure with Sweden as the Reference Member State and is supported by results from four pivotal Phase III trials conducted in Europe and North America. More than 1,500 patients participated in these trials with 757 patients treated with ATX-101.
KYTH: 74.98 (-0.01)
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update
GlobeNewswire - Thu Aug 06, 3:22PM CDT
Westlake Village, Calif., Aug. 6, 2015 - KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter of 2015, and provided an update on recent developments.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration
GlobeNewswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration
PR Newswire - Wed Aug 05, 7:00AM CDT
Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA's stockholders. The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA
GlobeNewswire - Mon Jul 27, 4:45PM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's pending acquisition of KYTHERA.
AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)
GlobeNewswire - Mon Jul 27, 8:00AM CDT
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has received authorization from Health Canada to market BELKYRA(TM) "for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults." BELKYRA(TM) is a non-surgical treatment for improving the appearance and profile of submental fullness--more commonly known as "double chin," a facial aesthetic condition that affects both women and men. BELKYRA(TM) was recently launched in the U.S. under the brand name KYBELLA(TM).
KYTH: 74.98 (-0.01)
Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories
PR Newswire - Mon Jul 20, 8:25AM CDT
Equity Research Institute has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), and Impax Laboratories Inc. (NASDAQ: IPXL). Free research report on Pfizer can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PFE On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IPXL: 32.45 (-1.11), KYTH: 74.98 (-0.01), PFE: 35.29 (-0.02), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08)
Allergan (AGN) Eyes Dry Eye Disease Company, Oculeve - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 07, 8:00AM CDT
Allergan (AGN), which has been pretty active on the acquisition front, has now signed a deal to acquire development-stage medical device company, Oculeve.
AGN: 240.93 (-6.47), PGNX: 4.64 (-0.04), KYTH: 74.98 (-0.01), TEVA: 53.01 (-0.30)
KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.
PR Newswire - Fri Jun 26, 4:39PM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. ("Kythera" or the "Company"
(NasdaqGS: KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company's stockholders will only receive approximately $75 per share for each share of Kythera common stock they own. AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
Kythera Biopharmaceuticals (KYTH) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 26, 8:14AM CDT
Kythera Biopharmaceuticals (KYTH) is Overbought: Is A Drop Coming?
KYTH: 74.98 (-0.01)
KYTH INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of KYTHERA Biopharmaceuticals, Inc. Concerning the Sale of the Company to Allergan plc
BusinessWire - Wed Jun 24, 1:19PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (NASDAQGS: KYTH) ("KYTHERA" or "the Company"
in connection with the sale of the Company to Allergan plc (NYSE: AGN). AGN: 240.93 (-6.47), KYTH: 74.98 (-0.01)
